Literature DB >> 27734235

Is There Saturation in the Conversion of Baicalein to Baicalin After Oral Chewable Tablets: Retrospective Evaluation of the Human Pharmacokinetic Data?

Nuggehally R Srinivas1.   

Abstract

Entities:  

Year:  2016        PMID： 27734235     DOI： 10.1007/s40261-016-0467-y

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  9 in total

Review 1.  The effects of baicalein and baicalin on mitochondrial function and dynamics: A review.

Authors:  Marcos Roberto de Oliveira; Seyed Fazel Nabavi; Solomon Habtemariam; Ilkay Erdogan Orhan; Maria Daglia; Seyed Mohammad Nabavi
Journal:  Pharmacol Res       Date:  2015-08-28       Impact factor: 7.658

2.  Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in Healthy Chinese Volunteers.

Authors:  Hongxian Pang; Wei Xue; Aixin Shi; Min Li; Yang Li; Guoying Cao; Bei Yan; Fan Dong; Wei Xiao; Guorong He; Guanhua Du; Xin Hu; Gang Cheng
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

3.  Ameliorative effects of baicalein in MPTP-induced mouse model of Parkinson's disease: A microarray study.

Authors:  Li Gao; Chao Li; Ran-Yao Yang; Wen-Wen Lian; Jian-Song Fang; Xiao-Cong Pang; Xue-Mei Qin; Ai-Lin Liu; Guan-Hua Du
Journal:  Pharmacol Biochem Behav       Date:  2015-04-18       Impact factor: 3.533

Review 4.  Baicalein--an intriguing therapeutic phytochemical in pancreatic cancer.

Authors:  Graham Donald; Kathleen Hertzer; Guido Eibl
Journal:  Curr Drug Targets       Date:  2012-12       Impact factor: 3.465

Review 5.  Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives.

Authors:  N R Srinivas
Journal:  Xenobiotica       Date:  2010-05       Impact factor: 1.908

6.  Role of metabolism by intestinal microbiota in pharmacokinetics of oral baicalin.

Authors:  Mi Jeong Kang; Gyu Sub Ko; Do Gyeong Oh; Jin Sung Kim; Keumhan Noh; Wonku Kang; Won Ki Yoon; Hyoung Chin Kim; Hye Gwang Jeong; Tae Cheon Jeong
Journal:  Arch Pharm Res       Date:  2013-06-18       Impact factor: 4.946

7.  Baicalein inhibits α-synuclein oligomer formation and prevents progression of α-synuclein accumulation in a rotenone mouse model of Parkinson's disease.

Authors:  Qi Hu; Vladimir N Uversky; Mengyang Huang; Huicong Kang; Feng Xu; Xiaoyan Liu; Lifei Lian; Qiming Liang; Hong Jiang; Anding Liu; Cuntai Zhang; Francisco Pan-Montojo; Suiqiang Zhu
Journal:  Biochim Biophys Acta       Date:  2016-07-15

8.  Baicalein attenuates astroglial activation in the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinson's disease model by downregulating the activations of nuclear factor-κB, ERK, and JNK.

Authors:  Eunjin Lee; Hee Ra Park; Seung Taek Ji; Yujeong Lee; Jaewon Lee
Journal:  J Neurosci Res       Date:  2013-10-28       Impact factor: 4.164

Review 9.  Role of Intestinal Microbiota in Baicalin-Induced Drug Interaction and Its Pharmacokinetics.

Authors:  Keumhan Noh; Youra Kang; Mahesh Raj Nepal; Ki Sun Jeong; Do Gyeong Oh; Mi Jeong Kang; Sangkyu Lee; Wonku Kang; Hye Gwang Jeong; Tae Cheon Jeong
Journal:  Molecules       Date:  2016-03-10       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.